Patients with advanced stomach cancer lived longer on sonesitatug vedotin than on standard treatment, according to new trial results.
Kaitlyn M. Le
Advertisement
Kaitlyn is a Content Associate at CURE®, where she covers the intersection of science and storytelling in oncology. She studied Journalism and Biomedical Engineering at California Polytechnic State University, San Luis Obispo. Her background spans clinical research and patient care, bridging communication gaps between providers and patients. In her free time, she enjoys traveling, hiking, creating music, and fashion.
Email her at [email protected]
Articles by Kaitlyn M. Le
Tecvayli plus Talvey cut the risk of disease progression or death by 89% in patients with relapsed multiple myeloma, according to new trial results.
Advertisement
Latest Updated Articles
Tecvayli-Talvey Combo Cuts Myeloma Progression Risk by 89%Published: July 24th 2026 | Updated: July 24th 2026
Advertisement
Advertisement
Trending on CURE
1
Why I Chose a Treatment Break After Years of Living With Stage 4 Ovarian Cancer
2
Cancer Survivorship Changed My Body: One Day in a Factory Showed Me Just How Much
3
At ASCO, Liver Cancer Advocate Urges Annual CT Scans to Catch HCC
4
Her Oncologist Said, 'If You Were My Daughter, Do This'
5